Gallagher MD, PhD, with Vanderbilt University School of Medication. Gallagher will receive the award through the AAN’s 62nd Annual Meeting in Toronto, april 10 through April 17 kept, 2010. Named for two epileptologists who made excellent contributions to the epilepsy field, the Dreifuss-Penry Award recognizes doctors in the first stages of their careers who have made an independent contribution to epilepsy research. There are many forms of epilepsy, some of which are caused partly by genetic factors. Gallagher’s research targets juvenile myoclonic epilepsy that begins in childhood or adolescence and consists of mutations in one or multiple genes that may lead to excessively excitable nerve cells and seizures. Gallagher will highlight his study at the AAN Awards Plenary Session through the AAN Annual Getting together with on Thursday, 15 April.Fox Base today announced that it offers awarded $1. ‘Our Foundation’s top priority is the development of a disease-modifying treatment for PD, the most significant unmet need of Parkinson’s individuals,’ said Todd Sherer, PhD, CEO of MJFF. Schneeberger. Safra Core System for PD Research, we have been able to bring a short pre-clinical research of PD01 in to the clinic. This latest award will take our partnership to the next level, while improving the Foundation’s presence in Austria and in European countries on the whole, further solidifying MJFF as a worldwide leader in PD study and treatment.’ Pre-clinical studies also show that the PD01 vaccine stimulates your body’s immune system to produce antibodies that bind to the proteins alpha-synuclein, clearing it from the brain and slowing disease progression.